drugset / Trial / NCT03476174
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
Phase 2
Terminated
1 enrolled
Ralph Hauke
Nebraska Cancer Specialists Methodist Estabrook Cancer Center · collabPrometheus Laboratories · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this single arm phase 2 trial is to assess the response rate \[complete response (CR) + partial response (PR)\] of sequential therapy of pembrolizumab followed by HD IL-2 in subjects with stage IV malignant melanoma. Response assessment will be performed after pembrolizumab therapy, and response reassessment will be performed after HD IL-2 therapy using revised RECIST 1.1.
Timeline
- Start
- 2018-05-07
- Primary completion
- 2019-10-16
- Completion
- 2019-10-16
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 600000 iu/kg | Intravenous |